September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Increased Frequency of Herpes Simplex Virus-Specific Effector Memory CD26+CD8+ T Cells in HSV-Seropositive Ocular Herpes Asymptomatic Patients
Author Affiliations & Notes
  • Anthony B Nesburn
    Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, United States
  • Ruchi Srivastava
    Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, United States
  • Arif Khan
    Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, United States
  • Steven Wechsler
    Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, United States
  • Lbachir BenMohamed
    Gavin Herbert Eye Institute, University of California Irvine, Irvine, California, United States
  • Footnotes
    Commercial Relationships   Anthony Nesburn, None; Ruchi Srivastava, None; Arif Khan, None; Steven Wechsler, None; Lbachir BenMohamed, None
  • Footnotes
    Support  Grants EY14900, EY019896, EY024618, EY013191, The Discovery Eye Foundation, The Discovery Center for Eye Research, and a Research to Prevent Blindness Challenge grant.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3318. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Anthony B Nesburn, Ruchi Srivastava, Arif Khan, Steven Wechsler, Lbachir BenMohamed; Increased Frequency of Herpes Simplex Virus-Specific Effector Memory CD26+CD8+ T Cells in HSV-Seropositive Ocular Herpes Asymptomatic Patients
      . Invest. Ophthalmol. Vis. Sci. 2016;57(12):3318.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Herpes Simplex Virus type 1- (HSV-1-) specific CD8+ T cells protect mice from herpes infection and disease. However, the phenotype and function of human CD8+ T cells that are associated with the “natural” protection seen in HSV-1 seropositive healthy asymptomatic (ASYMP) individuals (who have never had clinical herpes disease) remains to be determined. CD26, a T cell activation antigen, is a key modulator in immune response with known dipeptidyl peptidase IV (DPPIV (12); EC 3.4.14.5) activity in its extracellular domain. CD26 not only acts as a functional dipeptidyl peptidase IV, but also binds strongly to adenosine deaminase. Considerable evidence suggests that CD26 can deliver a potent co-stimulatory signal to T-cells. This signal transducing property appears to be a property of its extracellular domain. In addition, CD26 appears to be a functional collagen receptor that may aid activated T-cells in localizing to inflammation in tissues.

Methods : In this study, we compared the expression of CD26 on peripheral HSV-specific CD8+ T cells from HLA-A*02:01 positive, HSV-1 seropositive ASYMP and symptomatic (SYMP) individuals (with a history of numerous episodes of recurrent ocular herpes disease).

Results : We report: (i) increased frequencies of HSV-specific effector memory (CD45RAlowCCR7low) CD26+CD8+ T cells in ten sequentially studied HLA-A*02:01 positive and HSV-1-seropositive ASYMP individuals compared to SYMP patients; (ii) robust and polyfunctional effector HSV-specific CD26+CD8+ T cell responses, assessed by a combination of tetramer frequency, granzyme B, granzyme K, perforin, CD107a/b cytotoxic degranulation, and IFN-g; were detected in ASYMP individuals, (iii) CD26 expression on HSV-specific CD8+ T cells correlated inversely with cell activation; and (iv) CD26 expression on HSV-specific effector CD8+ T cells negatively correlated with PD1 expression (P=0.0015).

Conclusions : Our findings reveal a novel CD26-mediated mechanism that might be involved in protective HSV-specific CD8+ T cell responses in ASYMP individuals, which spontaneously controls herpetic disease, and should guide the development of an effective T-cell-based herpes vaccine.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×